Deal Feed International Reports: Aileron Therapeutics Secures $33 Million in Series E Financing to Advance Its First-In-Class Cancer Drug
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today that it has secured $33 million in an extension to its Series E equity financing, bringing the total raised in this round to $48 million.
Deal details sourced by the Deal Feed Team from BusinessWire. (Opens in new window)
If you have any additional information about this or any other report featured on Deal Feed please email, [email protected], to contact our Deal Team.